Acurx Pharmaceuticals, Inc. (ACXP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert J. DeLuccia | Co-Founder & Executive Chairman | 701.54k | -- | 1946 |
| Mr. David P. Luci CPA, Esq., J.D. | Co-Founder, President, CEO, Corporate Secretary & Director | 668.98k | -- | 1967 |
| Mr. Robert G. Shawah CPA, CPA | Co-Founder & CFO | 470.29k | -- | 1967 |
Acurx Pharmaceuticals, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 4
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Corporate Governance
Upcoming Events
November 13, 2024 at 1:30 PM UTC
Acurx Pharmaceuticals, Inc. Earnings Date